MedTrace Logo

Docetaxel and Carboplatin as First-line Chemotherapy in Early Stage as Well as Advanced or Metastatic Ovarian Cancer

NCT00452985 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 30

Last updated 2012-08-14

No results posted yet for this study

Summary

Primary objective:

To assess response rate. To record the clinical improvement in relation to stage and histopathological grading.

Secondary objective:

To determine progression free survival. To find out overall survival. To evaluate the safety of the study regimen.

Conditions

  • Ovarian Neoplasms

Interventions

DRUG

Docetaxel

60-75 mg/m²

DRUG

Carboplatin

AUC 5

Sponsors & Collaborators

Principal Investigators

  • Rezaul-Farid Khan, Dr · Sanofi

Eligibility

Min Age
15 Years
Max Age
75 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2002-02-28
Primary Completion
2010-11-30
Completion
2010-11-30

Countries

  • Bangladesh

Study Locations

More Related Trials

Entities

Drugs
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00452985 on ClinicalTrials.gov